The information collection pertains to
the types of CMC postapproval manufacturing changes that FDA has
determined will likely have a minimal potential to have an adverse
effect on product quality (i.e., drug product identity, strength,
quality, purity, or potency), and therefore, should be documented
by applicants in an annual report under 21 CFR 314.70(d).
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.